Delving into the Latest Updates on Peptide Logic LLC with Synapse

作者: Cheung, Eugene ; Dischino, Daniel ; Rivière, Pierre J M ; Navarro, Victor M ; Talbi, Rajae ; McCarthy, Elizabeth A ; Steiner, Robert A ; Schteingart, Claudio D ; Leon, Silvia ; Maguire, Caroline ; Reed, Susan D

AbstractContextRecent evidence suggests that vasomotor symptoms (VMS) or hot flashes in the postmenopausal reproductive state and polycystic ovary syndrome (PCOS) in the premenopausal reproductive state emanate from the hyperactivity of Kiss1 neurons in the hypothalamic infundibular/arcuate nucleus (KNDy neurons).ObjectiveWe demonstrate in 2 murine models simulating menopause and PCOS that a peripherally restricted kappa receptor agonist (PRKA) inhibits hyperactive KNDy neurons (accessible from outside the blood–brain barrier) and impedes their downstream effects.DesignCase/control.SettingAcademic medical center.ParticipantsMice.InterventionsAdministration of peripherally restricted kappa receptor agonists and frequent blood sampling to determine hormone release and body temperature.Main Outcome MeasuresLH pulse parameters and body temperature.ResultsFirst, chronic administration of a PRKA to bilaterally ovariectomized mice with experimentally induced hyperactivity of KNDy neurons reduces the animals’ elevated body temperature, mean plasma LH level, and mean peak LH per pulse. Second, chronic administration of a PRKA to a murine model of PCOS, having elevated plasma testosterone levels and irregular ovarian cycles, suppresses circulating levels of LH and testosterone and restores normal ovarian cyclicity.ConclusionThe inhibition of kisspeptin neuronal activity by activation of kappa receptors shows promise as a novel therapeutic approach to treat both VMS and PCOS in humans.

mAbs

Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders

作者: Stratton, Harrison J. ; Riviere, Pierre J. M. ; Navratilova, Edita ; Maciuba, Stephanie ; Wisniewski, Kazimierz ; Lowitz, Joshua ; Porreca, Frank ; Lee, Grace ; Schteingart, Claudio D. ; Valadon, Philippe ; Almagro, Juan C. ; Dolatyari, Mahdi ; Glaser, Scott M. ; Bowden, Gregory D.

Prolactin (PRL) has recently been demonstrated to elicit female-selective nociceptor sensitization and increase pain-like behaviors in female animals.Here we report the discovery and characterization of first-in-class, humanized PRL neutralizing monoclonal antibodies (PRL mAbs).We obtained two potent and selective PRL mAbs, PL 200,031 and PL 200,039.PL 200,031 was engineered as human IgG1 whereas PL 200,039 was reformatted as human IgG4.Both mAbs have sub-nanomolar affinity for human PRL (hPRL) and produce concentration-dependent and complete inhibition of hPRL signaling at the hPRL receptor (hPRLR).These two PRL mAbs are selective for hPRL as they do not inhibit other hPRLR agonists such as human growth hormone or placental lactogen.They also cross-react with non-human primate PRL but not with rodent PRL.Further, both mAbs show long clearance half-lives after i.v. administration in FcRn-humanized mice.Consistent with their isotypes, these mAbs only differ in binding affinities to Fcγ receptors, as expected by design.Finally, PL 200,019, the murine parental mAb of PL 200,031 and PL 200,039, fully blocked stress-induced and PRL-dependent pain behaviors in female PRL-humanized mice, thereby providing in vivo preclin. proof-of-efficacy for PRL mAbs in mechanisms relevant to pain in females.

100 项与 Peptide Logic LLC 相关的药物交易

登录后查看更多信息

100 项与 Peptide Logic LLC 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

5

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

PL 200039 ( prolactin )	疼痛更多	临床前
GPCRs PAC (Peptide Logic) ( GPCR )	炎症更多	临床前
PL 200031 ( prolactin )	疼痛更多	临床前
LA-KOR Agonists (Peptide Logic) ( κ opioid receptor )	疼痛更多	临床前
LA‑SSTR4 agonists (Peptide Logic) ( SSTR4 )	疼痛更多	临床前